Changfan Lubiprostone Soft Capsules

1. Indications and Usage
Chronic Idiopathic Constipation: Indicated for the treatment of chronic idiopathic constipation in adults.
IBS-C: Indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adult women.
Opioid-Induced Constipation: Indicated for the treatment of opioid-induced constipation in adults with chronic severe pain.
2. Dosage and Administration
Recommended Dosage: The standard dosage is typically 24 mcg taken orally twice daily with food and water. Specific dosing regimens may vary slightly depending on the regulatory approval for specific indications.
Administration: Always take with food to reduce the risk of nausea. Swallow the capsule whole.
Renal/Hepatic Impairment: Use with caution in patients with severe renal impairment or end-stage renal disease, as safety and efficacy have not been fully established in these populations.
3. Mechanism of Action
CIC-2 Activation: Lubiprostone is a localized chloride channel activator that selectively activates type 2 chloride channels (CIC-2) located on the apical membrane of gastrointestinal epithelial cells.
Fluid Secretion: This activation leads to increased intestinal chloride and bicarbonate secretion, resulting in increased intestinal fluid. Consequently, bowel movements are increased and the transit of stool through the bowel is accelerated without altering plasma sodium and potassium concentrations.
4. Safety and Warnings
Nausea: Nausea is the most common adverse reaction. Taking the capsule with food significantly reduces the occurrence and severity of nausea.
Diarrhea: Diarrhea is a frequent side effect; dose reduction or interruption may be necessary if diarrhea becomes severe.
Ocular Disorders: Rare cases of bilateral acute angular glaucoma, retinal detachment, and miosis have been reported. Patients experiencing eye pain, visual changes, or swelling/redness in or around the eye should seek immediate ophthalmologic evaluation.
Intestinal Perforation: Caution is advised in patients with known or suspected bowel obstruction, severe constipation, or intestinal strictures due to the risk of increased intraluminal pressure leading to perforation.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: The most frequently reported adverse reactions include nausea, diarrhea, headache, abdominal pain, vomiting, abdominal distension, dizziness, and asthenia.
Clinical Research Results: Clinical trials have demonstrated that lubiprostone significantly increases the number of spontaneous complete bowel movements per week compared to placebo in patients with chronic idiopathic constipation and IBS-C, with a favorable overall safety profile.
6. Drug Interactions
CYP450 Metabolism: Lubiprostone is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes, making interactions with CYP-metabolized drugs highly unlikely.
P-gp Interactions: It is not a substrate or inhibitor of P-glycoprotein (P-gp), suggesting a low risk for transporter-mediated interactions.
Antacids: While no direct pharmacokinetic interaction has been established, antacids containing aluminum or magnesium may affect gastrointestinal motility, theoretically altering lubiprostone’s effects.
7. Pharmaceutical Information
Active Ingredient: Lubiprostone.
Dosage Forms: Typically available as soft capsules in 24 mcg strength.
Storage: Should be stored at controlled room temperature in the original container to protect from moisture and light. Avoid high temperatures.